Hamburg offers balanced sound bites from China trip

The FDA has never depended more on China for the policing of drugs destined for the U.S. And that's about $1.5 billion worth of imports. Simultaneously, the U.S. is enjoying unprecedented access to China's pharma supply chain. So says FDA Commissioner Margaret Hamburg following a week-long visit in China, reports the Wall Street Journal.

Hamburg provided some politically expedient sound bites during her tour, but few specifics. She says she's "feeling very encouraged by the partnership we've developed," and that Chinese officials are pursuing a "common agenda" to improve drug and food manufacturing and regulation. 

The report says also that Hamburg "dodged a question" about what she will report to Congress. Lawmakers have been aggressive in questioning her about Chinese imports, in particular the contaminated heparin of several years ago but also the growing quantities of API imports.

"China is a major producer of active pharmaceutical ingredients and we have had some very focused discussions on that very important component of the supply chain," she says in the report.

- here's the report


Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.